Deerfield Management Company L.P. Series C Purchases 3,412,590 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Deerfield Management Company L.P. Series C raised its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 378.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 4,314,340 shares of the company's stock after acquiring an additional 3,412,590 shares during the period. NewAmsterdam Pharma makes up about 2.1% of Deerfield Management Company L.P. Series C's holdings, making the stock its 13th largest position. Deerfield Management Company L.P. Series C owned 4.67% of NewAmsterdam Pharma worth $110,879,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI purchased a new position in NewAmsterdam Pharma during the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $80,000. KLP Kapitalforvaltning AS bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $154,000. Barclays PLC grew its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $221,000. Institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NAMS shares. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of "Buy" and a consensus price target of $43.00.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James N. Topper bought 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Down 4.2%

NAMS traded down $0.81 during trading on Tuesday, reaching $18.41. 390,052 shares of the company were exchanged, compared to its average volume of 621,314. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The company's 50-day moving average is $19.45 and its two-hundred day moving average is $21.26. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -9.79 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. Equities analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.